Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

| More on:
a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Resmed share price is down 3.5% in afternoon trading
  • The US-based company booked a 12% increase in revenue and a 9% increase in profit year over year 
  • Holders of Resmed shares on the ASX will receive 4.4 US cents per share as dividends on September 22

The Resmed CDI (ASX: RMD) share price is down around 3.5% at $33.42 in afternoon trading. This comes after the US-based sleep apnoea medical device company released its full-year results to the ASX this morning.

As my colleague James wrote, ResMed Inc (NYSE: RMD) booked a 12% increase in revenue year over year to US$3.6 billion. It finished the year with an underlying net profit of US$850.8 million, up 9% on FY21.

Revenue and profits up

As James points out, ResMed's underlying net profit was slightly above market consensus expectations of US$825.6 million.

A recall by competitor Royal Philips in June 2021 provided a revenue boost for ResMed in FY22.

Management estimates that US$60 million to US$70 million in incremental fourth-quarter revenue was related to the recall. That implies an annual total of US$220 million to US$260 million.

Inflation started to bite in FY22, with higher freight and manufacturing costs impacting margins.

Over FY22, the Resmed share price slipped by about 7%.

Resmed dividends up

ResMed declared a final quarterly cash dividend of 44 US cents, up 5% on the prior corresponding period. But that's what ResMed Inc shareholders (owners of the NYSE-listed shares) will get. It's different for ASX shareholders, who own Resmed CDI shares.

Remember ResMed is a US-domiciled company listed on the New York Stock Exchange. The Resmed shares listed on the ASX are CHESS depositary interests (CDIs) which "confer a beneficial interest in the underlying financial product to which it relates", explains the ASX.

This beneficial interest is on a ratio of 10:1 for owners of the ASX shares. So, Resmed CDI shareholders will receive 4.4 US cents per share as dividends. This currently converts to 6.2 cents in Australian currency. The payment date is 22 September.

So, why is the Resmed share price down?

The company exceeded consensus profit expectations, and it's going to pay a higher dividend this year. So why is the Resmed share price down?

Well, the dip might not have anything to do with investors' reactions to the results. The market as a whole is down today.

The S&P/ASX 200 Index (ASX: XJO) is off 0.73% and the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 1.81%.

In fact, healthcare is the second worst performing sector today behind the S&P/ASX 200 A-REIT Index (ASX: XPJ), which is down 1.87%. The only sectors in the green are energy and communications.

So, it might simply be a case of the Resmed share price being dragged down, along with many other ASX healthcare shares, by the broader sector and market today.

Should you invest $1,000 in Resmed Inc. right now?

Before you buy Resmed Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resmed Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 6 March 2025

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
Healthcare Shares

3 reasons to buy this surging ASX All Ords healthcare share today

A top expert forecasts more outperformance from this rocketing ASX healthcare stock.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Down 11% in 2025, are CSL shares a good buy right now?

Are CSL shares likely to go up from here?

Read more »

Three healthcare workers look and point at at medical image
Healthcare Shares

Pro Medicus to buyback 10.4 million shares. What does this mean?

Is this a sign to buy?

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Why I think this ASX small-cap stock is a bargain at 40 cents

Here’s why this business has a compelling outlook...

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

One likely reason the market has soured on Pro Medicus

Is there opportunity for brave investors?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Hedge the rise in your health insurance premium with these 2 ASX stocks

Sick of price rises? Get on the other side of the transaction.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

2 ASX 200 biotech stocks announcing big news today

Let's see how the market has responded to these announcements.

Read more »